A co-founder of Inhibrx, Quinn leads target identification and validation, therapeutic lead selection and oversees the pipeline development strategy. Prior to founding Inhibrx, he spent 10 years at the Genomics Institute of the Novartis Research Foundation (GNF). Quinn led groups of Ph.D./M.D. level investigators in the conception and generation of novel target identification and validation platforms. Quinn was a key member of the team that transitioned the first GNF therapeutic antibody from bench-top to clinical trials. His research on cell death at the Stanford-Burnham-Prebys Medical Discovery Institute has been highly cited. Quinn received his Ph.D. in biochemistry from the University of Utah School of Medicine.